Category: Eric Lefkofsky
Tempus Labs is a revolutionary creator of groundbreaking technology concerning cancer drugs and therapies. They use gene therapy and gene editing to help patients with diseases that were until previously untreatable. The company was founded less than five years ago by Eric Lefkofsky.
The results of Tempus’s labor has resulted in several of their products being FDA approved. Voretigeneneparvovec-rzyl, which is marketed at Luxturna, was approved by the US Food and Drug Administration right before the New Year. The drug was created to treat a rare form of vision loss that results from mutations of a certain gene.
Tempus, under the leadership of Lefkofsky also developed glucose sensors that can be used to directly dose insulin on a basis varying from person to person. The new discovery, which has also been FDA approved, is marketed as Abbot’s FreeStyleLibre Flash glucose monitor and is applied to the arm instead of requiring a person to prick their finger. The monitor can be set up to send data directly to a smartwatch or phone.
Who is Eric Lefkofsky?
Eric Lefkofsky is the co-founder and CEO of medical technology innovator Tempus. In 2006, he created the Lefkofsky Family Foundation, a charitable organization where he assists cancer patients in having a more fulfilling life. Lefkofsky graduated from the University of Michigan and the University of Michigan Law School. As well as being involved in advancement of medicine, he voyages in the worlds of art and theater. Other companies that Lefkofsky is involved in include, but are not limited to, Trustee of Luie Children’s Hospital of Chicago, The Art Institute of Chicago and Steppenwolrd Theatre Company.
Lefkofsky Family Foundation
The Lefkofsky Foundation was founded in 2006 by Eric Lefkofsky and his wife Liz with the purpose of advancing initiatives that relate to enhancing the lives of the community around them. The foundation primarily focuses medical research but also works to expand cultural initiatives in and around Chicago and is an advocate of human rights for women and young girls.
Eric Lefkofsky Info: www.crunchbase.com/person/eric-lefkofsky
Yafang Li, PhD. led a Dartmouth research team in a study on the role gene-smoking interactions play in the etiology of lung cancer. The study which was published in Carcinogenesis identified three new lung cancer genetic biomarkers. The study revealed three SNP’s(single nucleotide polymorphisms) in DNA that form the foundation of our susceptibility to developing cancer. Two of the SNP’s were for the risk of non-small cell lung cancer, and the other was for the risk of squamous cell lung cancer.
These three SNP’s the study identified provided potential candidate biomarkers for lung cancer risk screening and intervention. The team’s findings were limited to the smoking behavior and non-small cell lung cancer risk in the Caucasian population. Because of this restriction, the results are not applicable to other ethnicities, but suggest a breakthrough in the treatment of lung cancer is on the horizon.
The breakthrough that these results make in cancer research is good news for all who long for a cure. Eric Lefkofsky like so many others believes that a cure for cancer can be found if the way we diagnose and treat the disease change. Lefkofsky has donated millions of dollars towards cancer research. In 2006 he and his wife established the Lefkofsky Family Foundation. This foundation is a private charitable foundation that uses high-impact initiatives to enhance the lives close to their community in Chicago. The foundation provides funding for education, healthcare, medical research, and arts and culture.
Mr. Lefkofsky is an American entrepreneur who wears many hats. A graduate of the University of Michigan, he is an adjunct professor at the University of Chicago; he is the co-founder and CEO of TEMPUS; the co-founder of Echo Global Logistics; and he is involved on a corporate level with Inner Workings, Mediacean, and Uptake.. It is his work with Tempus, however, that will benefit most from the findings of Dr. Li’s study.
Tempus is a health tech company that’s “building the infrastructure to modernize cancer treatment.” Tempus collects and analyzes genomic data to uncover ways that will enable physicians to provide more precise and personalized treatments for their patients. The data driven treatment decisions used by Tempus analyzes “a patient’s genetic code in the context of molecular therapies” seems a good fit for the Dartmouth’s study groups findings. Tempus believes that their efforts will propel the next advancement in healthcare. We all stand on the shoulders of men like Lefkofsky as we wait for it.
To know more click here